annual EBITDA:
-$272.60M-$47.61M(-21.16%)Summary
- As of today (May 30, 2025), AXSM annual EBITDA is -$272.60 million, with the most recent change of -$47.61 million (-21.16%) on December 31, 2024.
- During the last 3 years, AXSM annual EBITDA has fallen by -$147.97 million (-118.73%).
- AXSM annual EBITDA is now -14720.27% below its all-time high of -$1.84 million, reached on December 31, 2013.
Performance
AXSM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$54.85M+$15.70M(+22.25%)Summary
- As of today (May 30, 2025), AXSM quarterly EBITDA is -$54.85 million, with the most recent change of +$15.70 million (+22.25%) on March 31, 2025.
- Over the past year, AXSM quarterly EBITDA has increased by +$10.60 million (+16.19%).
- AXSM quarterly EBITDA is now -3132.69% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$262.01M+$10.60M(+3.89%)Summary
- As of today (May 30, 2025), AXSM TTM EBITDA is -$262.01 million, with the most recent change of +$10.60 million (+3.89%) on March 31, 2025.
- Over the past year, AXSM TTM EBITDA has increased by +$23.71 million (+8.30%).
- AXSM TTM EBITDA is now -15342.27% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AXSM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.2% | +16.2% | +8.3% |
| 3 y3 years | -118.7% | -44.4% | -95.2% |
| 5 y5 years | -306.5% | -68.8% | -193.9% |
AXSM EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -118.7% | at low | -1064.0% | +43.2% | -95.2% | +12.3% |
| 5 y | 5-year | -306.5% | at low | -1064.0% | +43.2% | -193.9% | +12.3% |
| alltime | all time | <-9999.0% | at low | -3132.7% | +43.2% | <-9999.0% | +12.3% |
AXSM EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$54.85M(-22.2%) | -$262.01M(-3.9%) |
| Dec 2024 | -$272.60M(+21.2%) | -$70.54M(+16.5%) | -$272.60M(-8.7%) |
| Sep 2024 | - | -$60.56M(-20.4%) | -$298.59M(+0.1%) |
| Jun 2024 | - | -$76.05M(+16.2%) | -$298.41M(+4.4%) |
| Mar 2024 | - | -$65.44M(-32.2%) | -$285.72M(+27.0%) |
| Dec 2023 | -$224.99M(+28.3%) | -$96.53M(+59.9%) | -$224.99M(+20.5%) |
| Sep 2023 | - | -$60.38M(-4.7%) | -$186.68M(+11.8%) |
| Jun 2023 | - | -$63.37M(+1244.8%) | -$167.04M(+17.7%) |
| Mar 2023 | - | -$4.71M(-91.9%) | -$141.93M(-19.0%) |
| Dec 2022 | -$175.40M(+40.7%) | -$58.23M(+42.9%) | -$175.19M(+17.1%) |
| Sep 2022 | - | -$40.73M(+6.5%) | -$149.57M(+5.4%) |
| Jun 2022 | - | -$38.26M(+0.7%) | -$141.95M(+5.7%) |
| Mar 2022 | - | -$37.98M(+16.5%) | -$134.26M(+8.4%) |
| Dec 2021 | -$124.63M(+24.3%) | -$32.61M(-1.5%) | -$123.86M(+4.2%) |
| Sep 2021 | - | -$33.11M(+8.3%) | -$118.88M(+9.9%) |
| Jun 2021 | - | -$30.57M(+10.9%) | -$108.14M(+13.4%) |
| Mar 2021 | - | -$27.57M(-0.2%) | -$95.34M(-4.9%) |
| Dec 2020 | -$100.26M(+49.5%) | -$27.63M(+23.5%) | -$100.26M(+3.3%) |
| Sep 2020 | - | -$22.37M(+25.9%) | -$97.05M(+3.8%) |
| Jun 2020 | - | -$17.77M(-45.3%) | -$93.48M(+4.9%) |
| Mar 2020 | - | -$32.49M(+33.0%) | -$89.14M(+32.9%) |
| Dec 2019 | -$67.07M | -$24.42M(+29.9%) | -$67.07M(+29.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$18.80M(+39.9%) | -$51.98M(+26.2%) |
| Jun 2019 | - | -$13.44M(+29.1%) | -$41.18M(+15.3%) |
| Mar 2019 | - | -$10.41M(+11.5%) | -$35.72M(+19.9%) |
| Dec 2018 | -$29.79M(+8.1%) | -$9.34M(+16.7%) | -$29.79M(+8.2%) |
| Sep 2018 | - | -$8.00M(+0.3%) | -$27.53M(+7.5%) |
| Jun 2018 | - | -$7.98M(+78.1%) | -$25.61M(+5.1%) |
| Mar 2018 | - | -$4.48M(-36.7%) | -$24.38M(-11.6%) |
| Dec 2017 | -$27.56M(+1.9%) | -$7.08M(+16.4%) | -$27.56M(-0.2%) |
| Sep 2017 | - | -$6.08M(-9.8%) | -$27.62M(-3.9%) |
| Jun 2017 | - | -$6.74M(-12.0%) | -$28.75M(-0.3%) |
| Mar 2017 | - | -$7.66M(+7.3%) | -$28.83M(+6.6%) |
| Dec 2016 | -$27.05M(+135.8%) | -$7.14M(-0.8%) | -$27.05M(+6.7%) |
| Sep 2016 | - | -$7.20M(+5.5%) | -$25.34M(+25.7%) |
| Jun 2016 | - | -$6.82M(+16.0%) | -$20.16M(+30.7%) |
| Mar 2016 | - | -$5.88M(+8.3%) | -$15.42M(+33.5%) |
| Dec 2015 | -$11.47M(+109.0%) | -$5.43M(+168.5%) | -$11.55M(+43.2%) |
| Sep 2015 | - | -$2.02M(-2.9%) | -$8.07M(+4.2%) |
| Jun 2015 | - | -$2.08M(+3.6%) | -$7.74M(+36.8%) |
| Mar 2015 | - | -$2.01M(+3.2%) | -$5.66M(+55.2%) |
| Dec 2014 | -$5.49M(+198.4%) | -$1.95M(+14.8%) | -$3.65M(+114.8%) |
| Sep 2014 | - | -$1.70M | -$1.70M |
| Dec 2013 | -$1.84M | - | - |
FAQ
- What is Axsome Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Axsome Therapeutics?
- What is Axsome Therapeutics annual EBITDA year-on-year change?
- What is Axsome Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Axsome Therapeutics?
- What is Axsome Therapeutics quarterly EBITDA year-on-year change?
- What is Axsome Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Axsome Therapeutics?
- What is Axsome Therapeutics TTM EBITDA year-on-year change?
What is Axsome Therapeutics annual EBITDA?
The current annual EBITDA of AXSM is -$272.60M
What is the all time high annual EBITDA for Axsome Therapeutics?
Axsome Therapeutics all-time high annual EBITDA is -$1.84M
What is Axsome Therapeutics annual EBITDA year-on-year change?
Over the past year, AXSM annual EBITDA has changed by -$47.61M (-21.16%)
What is Axsome Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AXSM is -$54.85M
What is the all time high quarterly EBITDA for Axsome Therapeutics?
Axsome Therapeutics all-time high quarterly EBITDA is -$1.70M
What is Axsome Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AXSM quarterly EBITDA has changed by +$10.60M (+16.19%)
What is Axsome Therapeutics TTM EBITDA?
The current TTM EBITDA of AXSM is -$262.01M
What is the all time high TTM EBITDA for Axsome Therapeutics?
Axsome Therapeutics all-time high TTM EBITDA is -$1.70M
What is Axsome Therapeutics TTM EBITDA year-on-year change?
Over the past year, AXSM TTM EBITDA has changed by +$23.71M (+8.30%)